|John Gordon McVie|
13 January 1945 |
|Residence|| United Kingdom
|Alma mater||Edinburgh University, Scotland|
|Known for||Cancer research|
|Institutions||European Institute of Oncology
Cancer Research Campaign
|Doctoral advisor||Gordon Hamilton-Fairley|
Professor John Gordon McVie (born 13 January 1945) is an international authority on the treatment and research of cancer. Along with Umberto Veronesi he is the founding or of ecancer.org, an open-access cancer platform.
He has written over 300 peer-reviewed papers and orials as well as contributing to numerous books. He has served on several committees including the American Association for Cancer Research and the American Society of Clinical Oncology, and the boards of the National Cancer Institutes of France, Italy and the Netherlands. In the UK, he has served on the boards of cancer institutes including the Beatson Institute for Cancer Research, the Institute for Cancer Research, and The Christie.
He is currently Director of Cancer Intelligence, providing advisory services to the media, patients, pharmaceutical and biotechnology companies as well as publishing ecancer.org. McVie is currently the Clinical Consultant to the European Institute of Molecular Oncology (IFOM), and a Visiting Professor at King's College London. He chairs the Board of Proton Partners (International) Limited and is a non-executive director of Ellipses Pharma.
He has formulated several substantial additions to the field of cancer care including establishing localised, more pin-point, administration of chemotherapy, and encouraging the use of chemotherapy for the treatment of lung cancer throughout the EU. He has also emphasised the importance of adjusting a patient’s management according to their ethnicity.
McVie obtained his PhDs in science and medicine at Edinburgh University, and was appointed Foundation Senior Lecturer at the Cancer Research Campaign Oncology Unit (currently Beatson West of Scotland Cancer Centre) at the University of Glasgow. Under Gordon Hamilton-Fairley, he trained in the United States, spending sabbaticals in Paris, Sydney, Australia and Amsterdam.
During the 1980s, McVie spent time as a Consultant in Oncology at the Antoni van Leewenhoek hospital in Amsterdam. Throughout his time in the Netherlands he was also Clinical Research Director at the National Cancer Institute of the Netherlands. From this position he helped to establish the drug development office of the European Organisation for Treatment and Research into Cancer (EORTC). As President of EORTC, he set up the present Drug Development Group in Brussels, and with NCI support, the European New Drug Development Network. In the UK he was one of the architects of the Cancer Trials Networks in Scotland, Wales, and England, and was a founding member of the National Cancer Research Institute.
He was Director General of Cancer Research UK (CRUK), the largest cancer charity in the UK, from 1996 to 2002. During this time over 60 new drugs were taken from laboratory to clinical trial, and temozolomide and abiraterone emerged.